Rocket Pharmaceuticals Q2 EPS $(0.74) Misses $(0.72) Estimate
Portfolio Pulse from Benzinga Newsdesk
Rocket Pharmaceuticals (NASDAQ:RCKT) reported a Q2 EPS of $(0.74), missing the analyst consensus estimate of $(0.72) by 2.78%. This represents a 9.76% improvement over the $(0.82) loss per share from the same period last year.
August 05, 2024 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rocket Pharmaceuticals reported a Q2 EPS of $(0.74), missing the analyst estimate of $(0.72) by 2.78%. However, this is a 9.76% improvement from the $(0.82) loss per share in the same period last year.
The EPS miss is likely to have a negative short-term impact on the stock price as it fell short of analyst expectations. However, the year-over-year improvement in EPS may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100